Oxford Nanopore appoints Peter Allen as Non-Executive Director
Oxford Nanopore Technologies Ltd announced the appointment of Peter Allen ACA to its board.
Peter Allen joins the board of Oxford Nanopore as non executive Director with broad, senior experience in the life sciences industries. He currently serves as Non-Executive Chairman on the Boards of ProStrakan Group plc, Chroma Therapeutics Ltd and Proximagen Neuroscience plc.
Previously, Peter was Chief Financial Officer of the electronics company Abacus Group plc from April 2005 until the company was sold to Avnet Inc in January 2009. Prior to this he was Chief Financial Officer of Celltech Group plc between 1992 and 2004. In addition to managing Celltech's flotation process in 1993, Peter played a key role in several strategic acquisitions, including Chiroscience Group plc, Medeva plc and Oxford Glycosciences plc. In 2003 Peter was also appointed Deputy Chief Executive Officer of Celltech until the company was sold to UCB in 2004.
Oxford Nanopore also announces the retirement of Riccardo Pigliucci from his role as non executive director, after serving nearly five years on the board.
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.